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Six novel 4-hydroxycoumarin derivatives were rationally synthesized, veriﬁed, and characterized by molecular docking using
crystal HIV-1 protease. Molecular docking studies predicted antiprotease activity of (7) and (10). The most signiﬁcant functional
groups,responsiblefortheinteractionwithHIV-1proteasebyhydrogenbondsformationarepyranoxygen,atom,lactonecarbonyl
oxygen and one of the hydroxyl groups. The newly synthesized compounds were biologically tested in MT-4 cells for inhibiting
HIV-1 replication, exploring the protection of cells from the cytopathic eﬀect of HIV measured by cell survival in MTT test.
One derivative −7 showed 76–78% inhibition of virus infectivity with IC50 = 0.01nM, much less than the maximal nontoxic
concentration (1mM). Antiprotease activity of 7 in two diﬀerent concentrations was detected to be 25%. Nevertheless, the results
of study of (7) encourage using it as a pharmacophore for further synthesis and evaluation of anti-HIV activity.
1.Introduction
The retroviral protease (PR) of human immunodeﬁciency
virustype1(HIV-1)isoneofthekeyenzymesforvirusrepli-
cation. It cleaves protein and glycoprotein precursors to yield
active viral enzymes and structural proteins. The inactive
HIV-1PRleadstononinfectiousvirions.Thisfactstimulated
searchofpotentsubstanceswithantiproteaseactivityinhibit-
ing HIV-1 replication. During the past 12 years, a number
of peptidomimetic analogs—inhibitors of HIV-1 PR (PIs)—
have been clinically introduced, but the largest part of them
show poor pharmacological characteristics such as bad oral
bioavailability, rapid clearance, and tolerability problems—
often associated with lypodystrophy and dyslipidemia [1].
Also,becauseofbeingpeptidomimetics,viralisolatesquickly
demonstrate a high degree of resistance and cross-resistance
even when using the members of the group before PIs were
put on the market [2].
Development of new nonpeptidic PIs, such as Tipranavir
and Darunavir, showed an impressive potency against PI-
resistant mutants, so remaining an important option for
patients harboring such resistance [3]. This is the rea-
son to search for novel nonpeptidic substances—inhibitors
of HIV-1 protease. Experimental data on some nonpep-
tidic substances—4-hydroxycoumarins (Figure 1)a n d4 -
hydroxypyran derivatives inhibiting HIV-1 PR, support this
idea [4].
Being for long years interested in synthesis and eval-
uation of a range of nonpeptidic substances such as 4-
hydroxycoumarin derivatives [5–9], we were encouraged to2 ISRN Pharmaceutics
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Figure 1: Structure of 4-hydroxycoumarin.
extend these experiments. Here, a number of new syntheses
are presented, accompanied with molecular docking experi-
mentsusingcrystalenzymeandbiologicalactivityevaluation
of novel and promising 4-hydroxycoumarin derivatives.
2. Results andDiscussion
2.1. Synthesis of 4-Hydroxycoumarin Derivatives
2.1.1. Synthesis of Arylmethylene-β-Ketoesters [10]. Diﬀer-
ently substituted aromatic aldehydes are used for synthe-
sis of arylmethylene-β-ketoesters via Knoevenagel reaction
with ethyl acetoacetate in the presence of piperidine as a
basic agent and glacial acetic acid. These arylmethylene-β-
ketoesters may be presented as in Figure 2.
A reaction of 4-hydroxybenzaldehyde and 2,4-pentane-
dione was also performed in the same conditions as above
mentioned. The isolated product was 3-(4-hydroxy)phenyl-
methylene-2,4-pentanedione (6)[ 11], see Figure 3.
2.1.2. The Michael Addition of Arylmethylene-β-Ketoesters
and Arylmethylene-2,4-Pentanediones to 4-Hydroxycoumarin.
The second step of the reaction is an addition of the
obtained arylmethylene-β-ketoesters with 4-hydroxycouma-
rin through the Michael reaction, by using sodium methox-
ide or piperidine as a basic agent [10]. This reaction can be
expressed as in Figure 4.
3-(4-Hydroxy)phenylmethylene-2,4-pentanedionereact-
ed with 4-hydroxycoumarin at the reﬂuxing and the pres-
ence of piperidine. The product of the Michael addi-
tion was 3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-hydrox-
yphenyl)methyl]pentane-2,4-dione (12)[ 11], see Figure 5.
2.2. Molecular Docking. The interaction of HIV-1 pro-
tease by molecular docking with some new synthesized 4-
hydroxycoumarin derivatives was investigated. Experimental
data for the activity of some 4-hydroxycoumarins were used
for comparison.
Preliminary molecular docking was made based on
known 4-hydroxycoumarin derivatives, which have inhibit-
ing activity of HIV-1 protease (Table 1)[ 4]. The grid is
chosen to oversize the ligand which is previously bound to
the enzyme (in this case 7 ˚ A size of the grid was chosen).
The G-score and E-model functions values have been
obtained by this method. They are called scoring function
and they are abstract equivalents of ΔGbind. These functions
take into account the free energy due to the solvent eﬀects,
conformational changes in protein and the ligand, interac-
tions between protein and the ligand (hydrogen bonds, ionic
interaction, and van der Waals forces), free energy loss of
freezing of internal rotation of protein and the ligand, free
energy loss in translational and rotational energy, caused by
association of the two molecules, and the free energy due
to changes in vibrational mode (usually ignored). If these
values are more negative for one ligand, this means that the
binding capability of this ligand is better. When the ligand
shows binding capability in one determined conformation,
the program shows this as a “good pose”.
This enzyme consists of two polypeptide chains and it is
from the aspartyl protease family with two aspartate residues
lying at the bottom of the active site. We used crystallo-
graphic structure of the retroviral HIV-1 protease, bound
with a peptidomimetic inhibitor BEA369 from Protein Data
Bank with pdb code 1EBY.
Itcanbeconcludedthatligand(1)hasthestrongestbind-
ing capability to HIV-1 protease. The results of molecular
docking conﬁrm the experimental data about ligand (1).
Concerning ligands (1)–(5), the G-score and E-model
values from molecular docking, for the group of tested
compounds, are shown in Table 2.
The interactions between the investigated 4-hydroxy-
coumarin derivatives and the active sites of the enzyme HIV-
1 protease are realized by hydrogen bonding and the van der
Waals interactions. The most active compound for example,
with the best binding activity, is compound (10), according
ligands (1)–(4) (based on the values of the scoring func-
tions). This fact probably dues to a formation of hydrogen
bonds between pyran oxygen atom, lactone carbonyl oxygen,
and one of the hydroxyl groups (in metaposition) attached
to the aromatic ring from the side chain. The van der
Waals forces of attraction also contribute for a good binding.
According to ligand (5), the most active is compound (7).
There are two hydrogen bonds for compound (7)w i t h
participation of pyran oxygen atom, carbonyl oxygen atom
from the lactone ring and one and corresponding protein
fragments. The van der Waals interactions of attraction, in
whichprobablym-nitrogroupisparticipatingwithoneofits
oxygen atoms are substantial to the binding. The compound
(7) seems to be more active than the experimental ligands.
2.3. Biological Activity in Cell Culture (MT-4 Cells). After
demonstrating the activity of some 4-hydroxycoumarin
derivatives towards isolated HIV-PR in molecular docking
experiments, it would be of interest to further test them
on HIV-1-infected MT-4 cells. The evaluation of anti-
HIV eﬀect was done by an in vitro rapid and sensitive
microtiter infection assay based on cytolysis quantitation
by vital dye (MTT) uptake as an endpoint for infection
[12]. Additionally, the eﬀect of inhibitors on endogenous
reverse transcriptase (RT) activity of HIV-1 III B-infected
MT-4 supernatants was considered as a marker for the ability
of blocking HIV-1 replication. MT-4 cells were infected
and incubated with each inhibitor for 72–96 hours, and
then RT activity was measured in the cell supernatants
accordingtoguidelinesintheHS-LentiKit-RTassay(Cavidi,
Sweden). A study of direct eﬀect of the newly synthesized
4-hydroxycoumarins on exogenous recombinant RT (rRT)
was also performed. Further, all the compounds were testedISRN Pharmaceutics 3
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R = –m-NO2 (ethyl 2-(3-nitrobenzylidene)-3-oxobutanoate) (1),
R = –p-NO2 (ethyl 2-(4-nitrobenzylidene)-3-oxobutanoate) (2),
R = –p-OH (ethyl 2-(4-hydroxybenzylidene)-3-oxobutanoate) (3),
R = –m,p-diOH (ethyl 2-(3,4-dihydroxybenzylidene)-3-oxobutanoate) (4),
R = –p-COOH (ethyl 2-(4-carboxybenzylidene)-3-oxobutanoate) (5),
R
where
Figure 2: General chemical structure and synthesis of arylmethylene-β-ketoesters.
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Figure 3: Synthesis of 3-(4-hydroxy)phenylmethylene-2,4-pentanedione (6).
for anti-HIV-1 PR activity. Table 3 represents the results of
microtiter infection assay using MTT and inhibition of HIV-
1 PR activity. The experiments were carried out in maximal
nontoxic concentration (MNC) for each compound.
First of all, it is seen that the compounds (8), (7), and
(12) have higher MNC meaning they are more cytotoxic
than the other three compounds. Only two of them (10)a n d
(7) inhibited viral replication in MT-4 cells, the inhibition
induced by (7) was remarkable (78%). Using 10x viral
dilutions, IC50 was established to be 0.01nM. No compound
showed eﬀect on both endogenous and exogenous RT. This
means that RT was not the target of the antiviral action. As
predicted by molecular docking studies, HIV-1 PR activity
was inhibited 24-25% were by (7) (5 separate evaluations
were done). The discordance found for (7) between the data
concerning inhibition of infectivity (about 75%) and pro-
tease activity (25%) could be explained by another activity,
such as l anti-integrase one. It is well known that some 4-
hydroxycoumarin derivatives are integrase inhibitors.
The experiments described in this paper expand the
earlier reported ones that 4-hydroxycoumarin derivatives
could serve as novel nonpeptidic PIs. Similarly to tipranavir
and darunavir, they could be eﬀective in patients with
developed resistance to peptidic PIs. Especially, (7)c o u l d
further be used as a pharmacophore to synthesize new more
active derivatives towards HIV-1 protease.
3. Conclusion
Six 4-hydroxycoumarin compounds were synthesized by
two-step synthesis. First step is the Knoevenagel reaction
between aromatic aldehydes and ethyl acetoacetate or acety-
lacetone. The second step is the Michael addition of the
obtained arylmethylene-β-ketoester or arylmethylene-2,4-4 ISRN Pharmaceutics
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R = –m-NO2 (ethyl 2-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3-nitrophenyl)methyl]-3-oxobutanoate)) (7),
R = –p-NO2 (ethyl 2-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl]-3-oxobutanoate) (8),
R = –p-OH (ethyl 2-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-hydroxyphenyl)methyl]-3-oxobutanoate) (9),
R = –m,p-diOH (ethyl 2-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(3,4-dihydroxyphenyl)methyl]-3-oxobutanoate) (10),
R = –p-COOH (ethyl 2-[(4-hydroxy-2-oxo-2H-chromen-3-yl)(4-carboxyphenyl)methyl]-3-oxobutanoate) (11),
Figure 4: The Michael addition of 4-hydroxycoumarin and arylmethylene-β-ketoesters.
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Figure 5: The Michael addition of 4-hydroxycoumarin and 3-(4-hydroxy)phenylmethylene-2,4-pentanedione (6).
pentanedione with 4-hydroxycoumarin. The products are
identiﬁed and characterized by 1H NMR, EI-MS, FTIR, and
element analysis.
Studying their binding activity to HIV-1 PR was per-
formed by molecular docking. The crystal HIV-1 PR, bound
with peptidomimetic inhibitor BEA369, was used. The high-
est binding activity is showing compound (10), according to
theexperimentalligands(1),(2),(3),and(4)andcompound
(7), according to ligand 5. This fact probably is due to a
f o r m a t i o no fh y d r o g e nb o n d sb e t w e e np y r a no x y g e na t o m ,
lactone carbonyl oxygen, and one of the hydroxyl groups (in
metaposition) attached to the aromatic ring from the side
chain. The van der Waals forces of attraction also contribute
to a good binding.
All six compounds were tested for anti-HIV-1 PR activity
in MT4 cells infected by HIV-1. The cell survival was
evaluatedbyMTTtestandalsothe%ofHIV-1PRinhibition
was measured. The highest inhibition of HIV-1 PR (25%)
and highest MT4 cell survival (78%) were demonstrated by
compound (7). Compound (7) could further be used as a
p h a r m a c o p h o r et os y n t h e s i z en e wm o r ea c t i v ed e r i v a t i v e s
towards HIV-1 PR.
4. ExperimentalPart
4.1. Synthesis of 4-Hydroxycoumarin Derivatives
4.1.1. Materials and Methods. All starting materials were
purchased from Merck, Sigma-Aldrich, and Fluka. They
are used without further puriﬁcation. Melting points are
measured in open capillary tubes on a B¨ uchi 535 melting
point apparatus. The IR spectra were recorded at Shimadzu
FT-IR 8101M spectrometer in nujol, and frequencies are
expressed in cm−1.T h e1H NMR spectra were recorded in
Brucker 250MHz in DMSO-d6 o ra c e t o n eu s i n gT M Sa sa n
internal standard (chemical shifts are reported in ppm units,
coupling constants (J) in Hz). Abbreviations are as follows:ISRN Pharmaceutics 5
Table 1: Structural information and binding activity of the experimental compounds.
Experimental ligands Substituents IC50 (μM) G-score E-model
(1) 4-hydroxy-3-(1-phenoxypropyl)-2H-chromen-2-one R = –C 3H6–O–C6H5,
R1 = H 2.7 −7.04 −62.5
(2) 3-(3,4-dimethoxybenzyl)-4-hydroxy-2H-chromen-2-one R = 3,4-dimethoxybenzyl,
R1 = H 84 −6.17 −60.1
(3) 3-(3,4-dimethoxybenzyl)-4-hydroxy-8-methyl-2H-
chromen-2-one
R = 3,4-dimethoxybenzyl,
R1 = –CH3
23 −6.17 −59.5
(4) 3-benzyl-4-hydroxy-8-phenyl-2H-chromen-2-one R = –benzyl,
R1 = –phenyl 8.1 −6.27 −57.0
(5) 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
(Warfarin)
R = C6H5CHCH2COCH3
R1 = H 18 −6.77 −58.8
Table 2: Scoring function values of the tested compounds, according to the experimental ligands (1)–(5).
Code
Ligand (1) Ligand (2) Ligand (3) Ligand (4) Ligand (5)
G-score E-model G-score E-model G-score E-model G-score E-model G-score E-model
(10) −6.96 −71.8 −7.31 −77.2 −6.90 −74.8 −6.18 −65.5 −7.08 −75.2
(9) −5.73 −61.0 −7.00 −72.0 −7.00 −73.4 −5.44 −56.3 −7.02 −73.1
(7) −5.63 −51.9 −7.46 −65.6 −6.04 −62.6 −5.97 −58.4 −7.85 −79.0
(8) −6.23 −67.5 −6.26 −68.2 −6.11 −64.6 −6.11 −65.2 −6.31 −69.0
(11) −5.78 −64.4 −6.04 −65.6 −5.94 −65.6 −5.84 −59.7 −6.00 −63.5
(12) −5.36 −47.9 −6.13 −58.7 −6.42 −61.1 −5.75 −53.6 −6.41 −61.0
Table 3: Anti-HIV-1 activity in cell culture (MT-4 cells) and inhi-
bition of HIV-1 protease activity.
Compound tested in
(MNC-μM)
Infection assay MTT-
% cell survival
% Inhibition of
HIV-1
protease activity
(8) (0.001) 0 0
(9) (0.0001) 0 0
(10) (0.0001) 30 16
(11) (0.0001) 0 0
(7) (0.001) 78 25
(12) (0.001) 0 0
Abacavir
(35 × 10−6 M) 98 Not tested
Pepstatin
(4.5 × 10−5 M) Not tested 100
reference inhibitors.
s: singlet, d: doublet, dd: double doublet, dq: double quartet,
dqui: double quintet, t: triplet, and m: multiplet.
Mass-spectral analysis was performed by electron ioniza-
tion on masspectrometer Hewlett-Packard 5973 at 70eV.
4.1.2. General Procedure for the Preparation of Arylmethylene-
β-Ketoesters. Aromatic aldehyde and ethylacetoacetate in
equimolar quantities are mixed in a round-bottomed ﬂask.
Piperidine (0.03mol) and glacial acetic acid (0.04mol) are
also added to the reaction mixture. The latter is stirred
at room temperature for 90 minutes. After 20mL ether
and/or 150mL distilled water are added to the reaction
mixture, the crystals with diﬀerent colors are formed. These
crystals are ﬁltered and washed. Then, they are dried at room
temperature and recrystallized in appropriate solvents—
mainly alcohols (ethanol, propanol, and 2-propanol) and
water.
Physical and Spectral Data
Ethyl2-(3-Nitrobenzylidene)-3-Oxobutanoate(1)[10]. White
crystals, m.p. 100–103◦C. The substance crystallizes from
water. Puriﬁed after recrystallization from isopropyl alcohol.
Yield: 17%. UV-VIS: λmax = 210, 266nm; FTIR (nujol):
1728.4, 1660.9, 1628.1, 1529.7, 780, 735cm−1; 1HN M R
(DMSO, 250MHz): δ = 0.9( t ,J = 7.1Hz, 3H) (methyl),
1.6 (s, 3H) (acetyl), 4.8 (q, J = 7.1Hz, 2H) (methylene),
7.09–7.02(m,1H)(aromatic),7.58–7.56(m,1H)(methyne),
7.92–7.87 (m, 1H) (aromatic), 8.36–8.31 (m, 1H) (aro-
matic), 8.66–8.64 (m, 1H) (aromatic); EIMS: m/z (%) = 263
(65.2, M+), 262 (20), 248 (99.1), 246 (100), 234 (19.1), 220
(32.1), 218 (51.8), 216 (15.7), 202 (35.7), 200 (24.3), 192
(13),180(18.3),176(66.09),174(27),160(10.4),152(21.7),
146 (13), 130 (20.9), 129 (36.5), 120 (17.4), 115 (19.1), 102
(35.7), 101 (47.8), 89 (13.9), 75 (29.6), 63 (9.6), 51 (13),
45 (2.6); TLC: Rf = 0.5 (hexane/acetone = 2:1); Anal.:
C13H13NO5, (263), (C, H) (calcd/found): % C 59.31/59.54,
% H 4.98/H 5.13.
Ethyl2-(4-Nitrobenzylidene)-3-Oxobutanoate(2)[10]. White
crystals. m.p. 160-161◦C. The substance crystallizes from
ether. Puriﬁed after recrystalization from isopropyl alcohol;
Yield: 66%; UV-VIS: λmax = 204, 270nm; FTIR (nujol):
1732.3, 1711.1, 1608.8, 1529.7, 1464.1, 844.9cm−1; 1HN M R
(Acetone, 250MHz): δ = 0.9 (t, J = 7.1Hz, 3H) (methyl),6 ISRN Pharmaceutics
1.3 (s, 3H) (acetyl), 2.8 (q, J = 7.1Hz, 2H) (methylene),
6.1 (s, 1H) (methyne), 7.68–7.62 (m, 2H) (aromatic), 7.95–
7.89 (m, 2H) (aromatic); 13C NMR (Acetone, 67MHz): δ =
15, 30, 45, 125, 130, 145, 165, 175, 200; TLC: Rf = 0,75
(hexane/chloroform/acetone/methanol = 5:3:2:1), Anal.:
C13H13NO5 (263), (C, H) = (calcd/found): % C 59.31/58.28,
% H 4.98/5.92, % N 5.32/3.52.
Ethyl2-(4-Hydroxybenzylidene)-3-Oxobutanoate (3)[13–16].
Yellow crystals, m.p 141–143◦C. The substance crystallizes
from ether. Puriﬁed after recrystallization from isopropyl
alcohol. Yield: 51%; UV-VIS: λmax = 206, 224, 286nm,
FTIR (nujol): 3325.7, 1732.3, 1641.6, 1597.3, 1462.2, 1205.7,
819.8cm−1; 1H NMR (Acetone, 200MHz): δ = 1.3( t ,J =
7.1Hz, 3H) (methyl), 2.3 (s, 3H) (acetyl), 4.3 (q, J = 7.1Hz,
2H) (methylene), 6.91–6.85 (m, 2H) (aromatic), 7.44–7.38
(m, 2H) (aromatic), 7.46–7.44 (m, 1H) (methyne), 10.5 (s,
1H) (hydroxyl).13C NMR (Acetone, 67MHz): δ = 30, 110,
135, 140, 160, 190; EIMS: m/z (%) = 234 (100, M+), 233
(57), 220 (10), 219 (69), 217 (17), 205 (15), 191 (25.4), 189
(38.25), 187 (11.3), 175 (8.7), 163 (11.3), 161 (11.3), 160
(28.7), 151 (28.7), 147 (68.7), 146 (11.3), 145 (37.4), 131
(7), 123 (30.4), 120 (9.6), 119 (20), 118 (19.1), 115 (2.6),
107 (6), 91 (20), 89 (19.1), 77 (7), 65 (11.3), 63 (12.1), 53
(5), 45 (0.9); TLC: Rf = 0.39 (hexane/acetone = 2:1); Anal.:
C13H14O4, (234), (C, H) = (calcd/found): % C 66.66/66.50,
% H 6.02/5.94.
Ethyl2-(3,4-Dihydroxybenzylidene)-3-Oxobutanoate(4)[17].
Brown-yellow crystals, m.p. 147.8–151◦C. The substance
crystallizes from water. Puriﬁed after recrystallization from
water. Yield: 19%; UV-VIS: λmax = 206, 252, 344nm;
FTIR (nujol): 3540, 1714.9, 1643.6, 1603, 1464.1, 1197cm−1;
1H NMR (DMSO, 250MHz): δ = 1.0 (t, J = 7.1Hz, 3H)
(methyl), 2.3 (s, 3H) (acetyl), 4.2 (q, J = 7.1Hz, 2H)
(methylene), 6.91 (dq, J = 8.13 Hz, 1H) (aromatic), 7.0 (dq,
J = 8.13Hz, 1H) (aromatic), 7.14–7.13 (m, 1H) (aromatic),
7.44–7.42 (m, 1H) (methyne), 8.4 (s, 2H) (hydroxyl); EIMS:
m/z (%) = 250 (100, M+), 249 (40), 235 (20), 233 (29.6),
222 (17.4), 205 (31), 189 (76.5), 177 (10.4), 176 (31.3),
163 (42.6), 161 (73.9), 147 (4.3), 134 (19.1), 117 (9.6), 103
(5.2), 89 (15.7), 88 (11.3), 77 (11.3), 69 (4.3), 62 (8.7), 51
(8.7); TLC: Rf = 0.4 (hexane/chloroform/acetone/methanol
=5:3:2:1);Anal.:C 13H14O5 (250),(C,H)(calcd/found):%
C 62.39/62.31, % H 5.64/5.64.
4-[2-(Ethoxycarbonyl)-3-Oxobut-1-en-1-yl]Benzoic Acid (5)
[10]. Yellow crystals, m.p. 148–150◦C. The substance crys-
tallizes from water. Puriﬁed after recrystallization from
ethanol; Yield: 57%; UV-VIS: λmax = 204, 292nm; FTIR
(nujol): band 3300–2400, 1736.1, 1689.8, 1608.8, 1460.3,
848cm−1; 1H NMR (DMSO, 250MHz): δ = 1.0( t ,J =
7.1Hz, 3H) (methyl), 2.4 (s, 3H) (acetyl), 4.2 (q, J = 7.1Hz,
2H) (methylene), 7.41–7.39 (m, 1H) (methyne), 7.59–7.53
(m, 2H) (aromatic), 7.96–7.91 (m, 2H) (aromatic), 13.23
(s, 1H) (carboxylic); EIMS: m/z (%) = 262 (64, M+), 261
(16.7), 247 (18.4), 233 (8), 218 (18.4), 217 (100), 191 (10),
189 (14.9), 179 (9.6), 175 (26.3), 173 (27.2), 171 (11.4),
155 (14.9), 151 (16.7), 147 (7.9), 131 (9.6), 129 (17.5),
115 (7.9), 103 (18.4), 101 (14.9), 91 (5.3), 77 (11.4), 75
(8.7), 63 (3.5), 51 (2.6), 45 (1.8); TLC: Rf = 0.33
(hexane/chloroform/acetone/methanol = 5:3:2:1); Anal.:
C14H14O5 (262), (C, H) (calcd/found): % C 64.12/64.44, %
H 5.38/5.26.
4.1.3. Procedure for the Preparation of 3-(4-Hydroxy)-Phe-
nylmethylene-2,4-Pentandione (6). 4-Hydroxybenzaldehyde
(3.66g, 0.03mol) and acetylacetone (5.14mL, 0.05mol) are
mixed in round-bottomed ﬂask. Piperidine (0.03mol) and
glacial acetic acid (0.04mol) are also added to the reaction
mixture. The latter is stirred at room temperature for 120
minutes. After 150mL distilled water are added to the
reaction mixture. Crystals with diﬀerent colors are formed.
These crystals are ﬁltered oﬀ and washed. Then they are
dried at room temperature and recrystallized in methylene
chloride.
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3-(4-Hydroxybenzylidene)-2,4-Pentanedione (6) [11]. Yel-
low-orange crystals, m.p. 126–129◦C. Yield: 22%, FTIR
(nujol): 3180, 1705, 1640, 1600, 1580, 1465, 1160, 900,
730cm−1; 1H NMR (DMSO, 250MHz): δ = 2.2 (s, 3H)
(acetyl), 2.4(s,3H) (acetyl), 4.8 (s, 1H) (methyne), 6.8–6.74
(m, 2H) (aromatic), 7.11–7.06 (m, 2H) (aromatic), 10.2 (s,
1H) (hydroxyl); EIMS: m/z (%) = 204 (100, M+), 189(100),
171 (18.5), 161 (100), 147 (100), 133 (9.2), 119 (74), 105
(6.7), 91(38.7), 77 (15.1), 63 (26), 51 (11.8), 45 (0.8);
TLC: Rf = 0.55 (hexane/chloroform/acetone/methanol =
5:3:2:1),Anal.:C 12H12O3 (204) (C, H) = (calcd/found): %
C 70.57/69.92, % H 5.92/5.85.
4.1.4. General Procedure for the Preparation of Condensation
Products with 4-Hydroxycoumarin. Arylydene-β-ketoester,
obtained in previous reaction, and 4-hydroxycoumarin are
mixed in equimolar quantities in 25–30mL methanol (used
as a solvent). Sodium methoxide (0.003mol) as a basic
agent is also added to the reagents. The reaction mixture
is boiled and stirred for 60 hours under reﬂux. The
reaction is controlled by TLC (hexane:acetone = 2:1 or
hexane: acetone:chloroform:methanol = 5:3:2:1).When
the quantities of reagents are depleted, the heating was
stopped. The residue from the reaction mixture was ﬁltered
oﬀ and was washed with hot water, in order to remove to
the 4-hydroxicoumarin which was not reacted. After that,
the residue is dried at room temperature and recrystallized
in appropriate solvent (methanol, ethanol, or 2-propanol).
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Ethyl2-[(4-Hydroxy-2-Oxo-2H-Chromen-3-yl)(3-Nitro-
phenyl)Methyl]-3-Oxobutanoate (7) [10]. White crystals,
m.p.135–140◦C.Puriﬁedafterrecrystallizationfromethanol.
Yield: 37% UV-VIS: λmax = 210nm; FTIR (nujol): 3335,
1732.3, 1674.4, 1620.4, 1529.7, 1068.7, 763, 736cm−1; 1H
NMR (DMSO, 250 MHz): δ = 1.0 (t, J = 6.83Hz, 3H)ISRN Pharmaceutics 7
(methyl), 1.9 (s, 3H) (acetyl), 3.9 (q, J = 6.83 Hz, 2H)
(methylene), 4.68–4.61 (m, 2H) (methyne), 7.23–7.17 (m,
1H) (aromatic), 7.4 (dq, J = 7.83 Hz, 1H) (aromatic), 7.52–
7.46 (m, 1H) (aromatic), 7.64–7.60 (m, 1H) (aromatic),
7.76–7.72 (m, 1H) (aromatic), 7.83–7.77 (m, 1H)(aromatic),
7.86–7.84 (m, 1H)(aromatic), 7.98–7.94 (m, 1H) (aromatic)
9.8 (s, 1H) (hydroxyl); EIMS: m/z (%) = 425 (4.4, M+), 382
(4.4), 361 (12.3), 336 (38.6), 320 (1.8), 308 (2.6), 294 (58.8),
278 (100), 266 (8.8), 257 (14.9), 249 (48.2), 248 (91.2), 239
(1.8), 220 (8.8), 205 (1.8), 176 (3.5), 165 (10.5), 139 (5.3),
130 (15.8), 120 (71.9), 101 (13.2), 92 (68.4), 85 (18.4), 75
(14.9), 64 (17.5), 51 (6); TLC: Rf = 0.34 (hexane/acetone =
2:1).
Ethyl2-[(4-Hydroxy-2-Oxo-2H-Chromen-3-yl)(4-Nitro-
phenyl)Methyl]-3-Oxobutanoate (8) [10]. White crystals,
m.p. 250–254◦C. Puriﬁed after recrystallization from
ethanol. Yield: 33%; UV-VIS: λmax = 206, 272nm; FTIR
(nujol): 3362.3, 1732.3, 1651.3, 1616.5, 1601.1, 833.3,
765.1cm−1; 1H NMR (DMSO, 250 MHz): δ = 1.0
(t, J = 6.83Hz, 3H) (methyl), 2.0 (s,3H) (acetyl), 3.9 (q,
J = 6.83Hz,2H)(methylene),4.40–4.36(m,1H)(methyne),
4.62 (dq, J = 4.25Hz, 1H) (methylene), 7.25–7.17 (m, 3H)
(aromatic), 7.38 (dq, J = 7.83Hz, 1H) (aromatic), 7.51–7.46
(m, 1H) (aromatic), 7.83–7.77 (m, 1H) (aromatic), 7.98–
7.94 (m, 1H) (aromatic), 10.0 (s, 1H) (hydroxyl); EIMS:
m/z (%) = 426 (0.8, M+), 380 (0.8), 368 (0.4), 343 (0.8),
327 (5.3), 317 (3.5), 302 (1.8), 284 (0.9), 274 (0.8), 256 (7),
242 (2.6), 230 (6.1), 213 (27.2), 202 (4.4), 187 (4.4), 176
(5.3), 163 (10), 162 (80.7), 149 (7.9), 134 (1.8), 121 (48.2),
120 (100), 105 (4.4), 92 (57), 77 (7.9), 63 (18.4), 51(6.1),
46 (1.8); TLC: Rf = 0.48 (hexane/acetone = 2:1); Anal.:
C22H19NO8 (426), (C, H) (calcd/found): % C 62.12/62.02,
% H 4.5/4.38, % N 3.29/3.21.
Ethyl 2-[(4-Hydroxy-2-Oxo-2H-Chromen-3-yl)(4-Hydroxy-
phenyl)Methyl]-3-Oxobutanoate (9) [10]. White crystals,
m.p. 195–197◦C. Puriﬁed after recrystalisatyion from
ethanol. Yield: 21% UV-VIS: λmax = 214, 280, 308nm;
FTIR (nujol): 3391.3, 1699.5, 1622.3, 1599.2, 1464.1, 821,
760cm−1; 1H NMR (DMSO, 250 MHz): δ = 1.0( t ,J =
6.83Hz, 3H) (methyl), 2.0 (s, 3H) (acetyl), 4.1 (q, J =
6.83Hz, 2H), 4.40–4.36 (m, 1H) (methyne), 4.62 (dq, J =
4.25Hz, 1H) (methylene), 6.87–6.82 (m, 2H) (aromatic),
7.23–7.17 (m, 1H) (aromatic), 7.4 (dq, J = 7.83Hz,
1H) (aromatic), 7.55–7.49 (m, 2H) (aromatic), 7.83–7.77
(m, 1H) (aromatic), 7.98–7.94 (m, 1H) (aromatic), 8.6 (s,
2H) (hydroxyl). EIMS: m/z (%) = 396 (0.09, M+), 364
(0.09), 350 (0.09), 321 (0.09), 307 (0.9), 279 (0.4), 266
(56.1), 265 (100), 249 (31.6), 237 (10.5), 221 (2.6), 210
(2.6), 181 (1.8), 165 (1.8), 153 (2.6), 146 (7), 130 (7),
121 (19.3), 118 (17.5), 102 (4.4), 92 (15.8), 85 (12.3), 76
(2.6), 63 (10.5), 53 (2.6), 46 (0.09); TLC: Rf = 0.48
(hexane/chlorophorm/acetone/methanol); Anal.: C22H20O7
(396),(C,H)(calcd/found):%C66.66/66.36,%H5.09/5.13.
Ethyl 2-[(3,4-Dihydroxyphenyl)(4-Hydroxy-2-Oxo-2H-
Chromen-3-yl)Methyl]-3-Oxobuta-Noate (10) [10]. Tiled-
red crystals, m.p. 243.4–247◦C. Puriﬁed after recrystalization
from isopropyl alcohol. Yield: 5%; UV-VIS: λmax = 208,
280nm; FTIR (nujol): 3451, 1732.3, 1662.8, 1608.8, 1460.3,
1180.6, 1109.2, 825.6, 756.2cm−1; 1H NMR (DMSO,
250MHz): δ = 1.2( t ,J = 6.83 Hz,3H) (methyl), 2.1 (s,
3H) (acetyl), 4.1 (q, J = 6.83Hz, 2H), 4.39–4.35 (m,1H)
(methyne), 4.62 (dq, J = 4.25Hz, 1H) (methylene), 6.86
(dq, J = 8.00Hz, 1H) (aromatic), 7.11 (dt, J = 2.5Hz,
1H) (aromatic), 7.25–7.17 (m, 2H) (aromatic), 7.38 (dq,
J = 7.83Hz, 1H) (aromatic), 7.83–7.77 (m, 1H) (aromatic),
7.98–7.94 (m, 1H) (aromatic), 8.1 (s, 3H) (hydroxyl); EIMS:
M+ is probably very unstable and it goes to a fragmentation
spontaneously. m/z (%) = 396 (0.09), 374 (0.9), 348 (0.5),
331 (0.9), 317 (5.3), 282 (8.8), 281 (12.3), 265 (9.6), 241
(1.8), 228 (26.3), 213 (0.9), 200 (48.2), 189 (1.8), 171 (8.8),
162 (93), 144 (7), 134 (5.3), 120 (100), 110 (58.8), 92
(74.6), 81 (8.8), 64 (35), 51 (11.4), 45 (3.5). TLC: Rf = 0.12
(hexane/chloroform/acetone/methanol = 5:3:2:1); Anal.:
C22H20O8, (412), (C, H) (calcd/found): % C 64.07/64.44, %
H 4.89/4.52.
4-[1-(4-Hydroxy-2-Oxo-2H-Chromen-3-yl)-2-(Ethoxycar-
bonyl)-3-Oxobutyl]Benzoic Acid (11) [10]. White crystals,
m.p. 150–155◦C. Puriﬁed after recrystalization from
methanol. Yield: 28%, UV-VIS: λmax = 208, 282, 308nm;
FTIR (nujol): 3442, band 3300–2400, 1732.3, 1693.7,
1612.7, 1462.4, 1109, 846.3, 756.2cm−1; 1H NMR (DMSO,
250MHz): δ = 1.0( t ,J = 6.83Hz, 3H) (methyl), 2.1 (s, 3H)
(acetyl), 3.9 (q, J = 6.83Hz, 2H) (methylene), 4.40–4.36
(m, 1H) (methyne), 4.62 (dq, J = 4.25Hz, 1H) (methyne),
7.24–7.17 (m, 1H) (aromatic), 7.38 (dq, J = 7.83Hz, 1H)
(aromatic), 7.50–7.45 (m, 2H) (aromatic), 7.62–7.57 (m,
2H) (aromatic), 7.83–7.77 (m, 1H) (aromatic), 7.98–7.94
(m, 1H) (aromatic), 12.83 (s, 2H) (carboxylic); EIMS: m/z
(%) = 424 (1.3, M+), 392 (0.4), 378 (17.5), 360 (1.8), 335
(48.2),317(19.3),307(9.6),294(44.7),293(34.2),265(6.1),
257 (50.9), 250 (22.8), 249 (100), 239 (5.3), 229 (1.8), 215
(12.3), 205 (1.8), 187 (2.6), 173 (2.6), 165 (4.4), 146 (2.6),
130 (6.1), 120 (19.3), 102 (6.1), 92 (30.7), 75 (6.1), 64 (8.8),
51 (2.6); TLC: Rf = 0.62 (hexane:chlorophorm:glacial
acetic acid = 10:10:4); Anal.: C23H20O8, (424) (C, H)
(calcd/found): % C 65.09/65.07, % H 4.75/4.9.
4.1.5. The Michael Addition between 3-(4-Hydroxybenzylide-
ne)-2,4-Pentanedione (SS-23) and 4-Hydroxycoumari. 3-(4-
Hydroxybenzylidene)-2,4-pentanedione (1.02g, 0.005mol)
and 4-hydroxycoumarin (0.81g, 0.005mol) are mixed in
slight excess of 4-hydroxycoumarin in 15–25mL methanol.
Piperidine (0.003mol) as a basic agent is also added to
the reagents. The reaction mixture is boiled and stirred
for 60 hours under reﬂux. The reaction is controlled
by TLC (hexane:chloroform:acetic acid = 10:10:4, hex-
ane:chloroform:acetic acid = 10:10:2, hexane:acetone =
2:1). When the quantities of reagents are depleted, the
heating was stopped. The residue from the reaction mixture
was ﬁltered oﬀ and was washed with hot water, in order
to remove the 4-hydroxicoumarin which was not reacted.
After that, the residue is dried at room temperature and
recrystallized in acetone.8 ISRN Pharmaceutics
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3-[(4-Hydroxy-2-Oxo-2H-Chromen-3-yl)(4-Hydroxyphen-
yl)Methyl]Pentane-2,4-Dione (12) [11]. White crystals, m.p.
209–210◦C. Yield 5%; 1H NMR (DMSO, 250MHz): δ =
1.5 (s, 3H) (acetyl), 2.0 (s, 3H) (acetyl), 4.55–4.5 (m,1H)
(methyne), 4.90 (dqui, J = 4.25Hz, 1H) (methyne), 6.93–
6.87 (m,2H) (aromatic), 7.2–7.17(m, 1H) (aromatic), 7.38
(dq, J = 7.83Hz, 1H) (aromatic), 7.55–7.50 (m, 2H)
(aromatic), 7.83–7.77 (m, 1H) (aromatic), 8.03–7.99 (m,
1H) (aromatic) 9.2 (s,2H) (hydroxyl); EIMS m/z (%) = 578
(0.8, M+), 523 (0.8), 495 (0.8), 467 (0.8), 439 (0.8), 409
(0.8), 395 (0.8), 382 (0.8), 368 (5.9), 354 (1.7), 3141 (2.5),
327 (0.8), 311 (6.7), 299 (1.7), 283 (5), 265 (58), 249 (16.8),
237 (6.7), 222 (1.7), 211 (2.5), 199 (1.3), 185(3.3), 165 (2.5),
146 (4.2), 121 (100), 100 (67.2), 85 (92.4), 65 (40.3), 53
(29.4); UV-Vis; λmax = 206,282 in ethanol; TLC: Rf = 0.38
(hexane/chloroform/acetone/methanol = 5:3:2:1), Anal.:
C21H18O6 (366), (C, H) = (calcd/found): % C 68.85/68.36,
% H 4.95/4.92.
4.2. Molecular Docking. All molecular docking calculations
are performed witsh Maestro Macromodel Glide programs
from Schrodinger package [18]. All of the structures (exper-
imentally tested and new) are minimized by Macromodel
program, using OPLS2005 force ﬁeld and 5000 iterations.
The X-ray structure of the enzyme HIV-1 protease, together
with the inhibitor BEA369, is obtained from Protein Data
Bank with PDB code 1EBY.
4.3. Cell Lines and Viruses. MT-4—a human lymphoblas-
toid suspension cell line, kindly provided by Gianfranco
Pancino— Institute Pasteur, (Unite de Regulation des Infec-
tions Retrovirales, Paris, France) represent a classical model
forexperimentalproductiveinfectionwithHIV-1IIIBstrain
andusedasaroutinetargetforstudyofeﬀectofputativeHIV
inhibitors in cell culture [19].
As a source of HIV-1, supernatants of H9/HTLV III B
line—a gift from Dr. R. Gallo (NIH, USA)— were used.
Supernatants were collected and centrifuged to remove the
cells,andvirusstockswerepreparedwithknownp24antigen
content (460pg/mL, Murex HIV Antigen mAB test), RT
activity (565.3pg RT/mL, HS-Lenti RT Activity Kit, Cavidi,
Sweden), and infectivity (2 × 106 infectious virions/mL,
microtiter infection assay) [20]. MT-4 and H9/HTLV III B
cells were grown in RPMI 1640 supplemented with 10% FCS
(invitrogen).
4.4. Cytotoxicity Tests and Antiviral Assays in Cell Culture.
The compounds under study were ﬁrst dissolved in DMSO
and further diluted in cell growth medium without fetal
serum. All the solutions were prepared ex tempore.
The following parameters were studied: cytotoxic con-
centration 50—CC50, where possible (the concentration
preventing death of 50% of MT-2 cells), maximal nontoxic
concentration—MNC, and inhibitory concentration 50-
IC50 (concentration inhibiting by 50% the viral replication).
CC50 and MNC were detected by MTT uptake assay [12].
IC50 was studied on MT-4 cells by microtiter infection
assay exploring the protection of cells from the cytopathic
eﬀect of HIV measured by MTT test [12]. Experiments
under conditions of acute infection were performed in 96-
well microplates with 6–8parallels/experiment. Cell controls
(MT-4 cells with medium only) and viral controls (virus
infected MT-4 cells) were run with each experiment. For
antivirus assays, HIV was added to each well to obtain
multiplicity of infection 0.1 except the cell controls. Virus
a t t a c h m e n tw a sa l l o w e df o ra nh o u ra t3 7 ◦C/5% CO2.T h e
plates were incubated for 72–96 hours at 37◦C/5% CO2.
After that, MTT test was performed as described [12]a n d
absorbance of viable cells was measured colorimetrically
at A540nm. For all experiments, the mean value of each
column was calculated (only if the values in A540 did
not diﬀer in ±10%). For antiviral assays, the mean values
of experimental and control rows were compared and the
percentage of cells protected (cell survival) under the appro-
priate concentration of the substance was plotted against
the concentration of the substance to obtain IC50. The cell
survival (% of cell protection) was calculated according to
the following formula:
%c e l lp r o t e c t i o n
=
A540X − A540 Control HIV
A540 Cell Control −A540 Control HIV
×100,
(1)
where X is the mean value of A540 of HIV-infected cells
treated with appropriate concentration of the compound
under study; control HIV is the mean value of A540 of HIV-
infected cells without any compound added; cell control is
the mean value of A540 of uninfected and untreated with
inhibitor cells.
As referent substance, ABC (Abacavir well-known nucle-
oside reverse transcriptase inhibitor—NRTI) [21] and pep-
statin were used.
4.4.1. Endogenous RT Activity and Direct Eﬀect of the
Compounds on RT. It was tested by HS-Lenti Kit-RT
assay (Cavidi, Sweden). The kit contains recombinant
RT (rRT) as a standard, which makes possible RT
quantitation. For endogenous RT assay, supernatants of
HIV-1 infected/uninfected MT-4 cells after incubation
with/withoutcompoundsweretestedaccordingtoguidelines
of manufacturer. The level of RT activity in supernatant was
calculated (in pg/mL) from the HIV-1 rRT standard set in
each kit. Direct eﬀect of the compounds on rRT activity was
measuredwiththesamekitandaimedtoproveRTasatarget
ofantiviralaction.Appropriatestepdilutionsoftheinhibitor
were prepared in control buﬀer and added to the reaction
mixture. The reaction was run for 3 hours at 33◦C.The RT
activity of standard dilutions was compared to that where
compounds were added or controls (where only incubation
mixture without compounds was added).
4.4.2. Detection of Antiprotease Activity by Tests Using Native
Viral PR. A method described earlier by Broglia et al., 2006ISRN Pharmaceutics 9
[19], for detection of recombinant protease activity was
modiﬁed to use native viral protease [22]. As a source of
native HIV-1 protease, again suspension of concentrated
viral stock (50x) from chronically infected H9/HTLV IIIB
cell supernatants was used. The lysis of viral particles and
releasing of the active enzyme (protease) was performed
using disrupting (lysis) buﬀer containing 2.5% Triton X-
100 in phosphate buﬀer. The concentration of the tissue
culture ﬂuid containing the virus was done by ultracentrifu-
gation in Biofuge Stratos, Heraeus, for 1 hour, at 4◦Ca n d
35000rev/min. The pellet was resuspended to obtain 50x
concentrate in disrupting buﬀer.
The following reaction mixture was prepared for each
experiment: 1000μL phosphate buﬀer (20mM, pH 6.0);
20μL HIV protease substrate III (1μg/mL, 760μM; Bachem,
Switzerland) in DMSO, prepared ex tempore;2 0μLe n z y m e
(stock HIV) taken from a solution containing 25μL disrupt-
ing (lysis) buﬀer + 100μL HIV-stock, incubated 40min at
37◦C prior to experiment.
The HIV-1 PR activity was measured using direct
spectrophotometric reading of the enzyme reaction sub-
strate utilization at 300nm, at room temperature and 1cm
pathlength, using T80 + UV-Vis spectrophotometer (PG
instruments). The initial reaction velocity (V0)w a sa d j u s t e d
to be 0.0020–0.0030 ΔAbs/min by varying the enzyme
activity (viral concentration). The tested compound and
the reference inhibitor (pepstatin used here) was added to
the reaction mixture prior to enzyme, in order to perform
the screening for inhibitory eﬀect. IC50 was deﬁned as the
concentration of the compound tested that decreases the
velocity of the reaction by 50% of the initial velocity without
tested (reference) compound.
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